期刊
ORAL DISEASES
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1111/odi.14378
关键词
leukoplakia; malignancy development; oral cavity; PDPN; podoplanin; prognosis
This study aimed to evaluate the utility of podoplanin as a predictive biomarker for malignancy development in patients with oral leukoplakia. Meta-analysis of 6 studies showed that high expression of podoplanin is associated with an increased risk of malignancy. However, there are limitations in the included studies that need to be addressed in future research.
Objectives The aim of this study is to identify and analyze the existing literature on the utility of podoplanin to predict the risk of malignancy development (MD) in patients previously diagnosed with oral leukoplakia (OL). Methods A systematic review and meta-analysis (SRMA) was performed though a search strategy using several electronic databases and a combination of keywords related to podoplanin and MD of OL, until 15 May, 2022 (PROSPERO CRD42022329326). Evaluation of the risk of bias (ROB) was performed using the Quality in Prognosis Studies Tool. The meta-analyses were estimated using fixed-effect models. Results From 421 articles, 6 studies were finally included, that enrolled 546 patients with OL, of whom 125 presented with an oral cancer during follow-up (32 to 90 months). Some limitations regarding the ROB were identified mostly related to small sample sizes, short follow-up times, lack of information on covariables in the included studies and lack of accuracy (including sensitivity and specificity). Meta-analysis of 6 studies reveal that high expression of podoplanin carries a pooled hazard ratio (HR) of 3.72 (95% CI, 2.40-5.76; p < 0.00001) for MD without statistical heterogeneity (I-2 = 0%, p = 0.53). Conclusion The results of this SRMA support the role of podoplanin immunohistochemical expression as a potential predictive biomarker to assess the risk of malignancy development in oral leukoplakia.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据